Seattle Children’s Therapeutics has opened a new study that will evaluate the safety and feasibility of CAR T-cell immunotherapy in patients with bone cancer. The ENLIGHTen-01 study is approved for patients ages 15 to 30 years old who have refractory or progressive osteosarcoma. It is Seattle Children’s first study of CAR T-cell therapy for this patient population.

“Seattle Children’s is dedicated to pursuing the advancement of next-generation therapies,” said Dr. Julie Park, a pediatric oncologist at Seattle Children’s who heads clinical and translational research at Seattle Children’s Therapeutics. “The launch of the ENLIGHTen trial underscores Seattle Children’s commitment to innovation in the fight against pediatric cancer.”

The ENLIGHTen-01 clinical trial will specifically assess the safety and tolerability of autologous “universal” CAR T cells when administered with UB-TT170, a proprietary small molecule fluorescein tag made by Umoja Biopharma, Inc.  UB-TT170 recently received clearance by the U.S. Food and Drug Administration (FDA) as an investigational new drug (IND).

Visit the study website for details: ENLIGHTen-01 study website.

Seattle Children’s is an international leader in research to cure childhood cancer by boosting the immune system with immunotherapy. We treat more types of relapsed or refractory childhood cancers using T-cell therapies than any other facility. To learn more about CAR T-cell therapy, visit Seattle Children’s T-cell Immunotherapy for Cancer.

For more information about the study please call 206-884-5333, email immunotherapyCRAs@seattlechildrens.org or read Umoja BioPharma’s press release.

About Seattle Children’s Research Institute

The Research Institute is one of the nation’s top five pediatric research centers. It is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Its Building Cure in downtown Seattle houses a multimillion-dollar cell processing facility that places the research institute among the few pediatric facilities that meet strict FDA requirements for manufacturing therapies. With 1 million square feet of clinical, laboratory and office space; a workforce of over 2,000 people; and over $211 million in total extramural funding for the 2021 fiscal year, the Research Institute is working toward the next wave of lifesaving discoveries.